

# 2019 NOVEL CORONAVIRUS (COVID-19) EPIDEMIOLOGICAL SURVEILLANCE PROTOCOL

Ministry of Health & Wellness, Jamaica

23 January 2020 Updated 15 April 2020 (Version 17)



## 2019 NOVEL CORONAVIRUS (COVID-19) EPIDEMIOLOGICAL SURVEILLANCE PROTOCOL

#### BACKGROUND

Coronaviruses (CoV) are a large family of viruses that cause illnesses ranging from less severe disease, such as the common cold, to more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). A novel coronavirus (nCoV) is a new strain that has not been previously identified in humans. Globally, novel coronaviruses emerge periodically in different areas, including SARS in 2002 and MERS in 2012<sup>1</sup>.

A novel (new) coronavirus, 2019 Novel Coronavirus (COVID-19), was identified in Wuhan City, Hubei Province, China in December 2019. The virus has caused significant morbidity and mortality in China and has spread to other countries.

Date of Transmission Pattern Jamaica	Category	Definition
Up to March 9, 2020	No cases	Countries/territories/areas with no cases
March 10, 2020	Sporadic cases	Countries/territories/areas with one or more cases, imported or locally detected
March 14, 2020	Clusters of cases	Countries/territories/areas experiencing cases, clustered in time, geographic location and/or by common exposures
Not Applicable	Community transmission	Countries/area/territories experiencing larger outbreaks of local transmission defined through an assessment of factors including, but not limited to: - Large numbers of cases not linkable to transmission chains - Large numbers of cases from sentinel lab surveillance - Multiple unrelated clusters in several areas of the country/territory/area

Jamaica reported its first case of COVID-19 on the 10<sup>th</sup> of March 2020.Transmission Patterns for Jamaica include:

Jamaica's epidemiological surveillance system will be used to detect and report on potential cases of COVID-19. The components of this surveillance system which will be used and enhanced as necessary are:

<sup>&</sup>lt;sup>1</sup> World Health Organization, 2020. Retrieved on January 20, 2020 from <u>https://www.who.int/health-topics/coronavirus</u>



- 1. The Class 1 Notification System (Case-based surveillance)
- 2. Sentinel Surveillance
- 3. Hospital Active Surveillance

The protocol below shall be adhered to for surveillance activities. There are five components to be considered in surveillance for the COVID-19. These are:

- A. Case Identification
- B. Case Reporting and Investigation (including contact tracing)
- C. Health Care Worker Surveillance
- D. Monitoring Community Transmission
- E. Specimen Collection and Testing
- F. Data Analysis and Interpretation
- G. Data Dissemination and Outputs

#### PURPOSE OF THESE GUIDELINES

To provide guidance on how to implement surveillance standards for COVID-19.

#### **OBJECTIVES**

The objectives of epidemiological surveillance of COVID-19 are:

- 1. To monitor trends of COVID- 19 in Jamaica
- 2. To establish epidemiological characteristics of COVID-19 infection in Jamaica
- 3. To inform risk assessment and decision-making.

Version 17 of the 2019 Novel Coronavirus (Covid-19) Surveillance Protocol includes the following updates:

- Definition of source of infection
- Updated contact tracing classification and sampling
- Health Care Worker Surveillance
- Reporting Guidelines for Enhanced Respiratory Infection Surveillance



### A. CASE IDENTIFICATION

COVID-19 by Public Health Order was made a Class 1 Notifiable Disease in March 2020.

#### **Case-based Surveillance**

#### Suspected Case<sup>2</sup>

✓ A person with acute respiratory illness (fever and at least ONE (1) sign or symptom of respiratory disease (e.g., Cough, Shortness of Breath)) AND a history of travel to or residence in a location reporting community transmission (see current WHO COVID-19 Situation Report) of COVID-19 disease during the 14 days prior to symptom onset.

#### OR

✓ A person with fever or any acute respiratory illness AND having been in contact (*this includes Bedroom, Household, Health-Care Workers, Conveyance and Casual Contacts*) with a confirmed or probable case of COVID-19 case, in the 14 days prior to the onset of illness.

## SUSPECTED CASE

Fever + Respiratory Symptoms AND Travel History

<u>OR</u>

Fever **or** Respiratory Symptoms AND Contact with a Confirmed or Probable Case

<u>OR</u>

Fever + Respiratory Symptoms AND Hospitalization Needed AND No Alternative Diagnosis

#### OR

✓ A person with severe acute respiratory infection (fever and at least ONE (1) sign or symptom of respiratory disease (e.g., Cough, Shortness of Breath)) AND requiring hospitalization AND in the absence of an alternative diagnosis that fully explains the clinical presentation.

## ACTION: NOTIFY PARISH HEALTH DEPARTMENT, ISOLATE, TAKE A SAMPLE AND COMPLETE CASE INVESTIGATION

<sup>&</sup>lt;sup>2</sup> World Health Organization, 2020 March 20. Global surveillance for COVID-19 caused by human infection with COVID-19 virus. Retrieved on March 24, 2020 from <a href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/surveillance-and-case-definitions">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/surveillance-and-case-definitions</a>



#### **Probable Case<sup>2</sup>**

✓ A suspected case for whom testing for COVID-19 virus is inconclusive.

OR

 $\checkmark$  A suspected case for whom testing for COVID-19 could not be performed for any reason.

#### **ACTION: MAINTAIN ISOLATION**

#### **Confirmed** Case<sup>2</sup>

✓ A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms.

### **ACTION: MAINTAIN ISOLATION**



### **B. CASE REPORTING AND INVESTIGATION**

#### Notification

COVID-19 is a Class 1 notifiable condition. This means all cases thought to be COVID-19 must be notified by the medical practitioner (public and private) within 24 hours of suspicion. Specifically, for COVID-19, the local Parish Health Department and National Surveillance Unit must be notified immediately. A **Class 1 Notification Form** must be submitted within 24 hours of initial notification (Appendix 1).

The Parish Medical Officer (Health) or designate, upon receiving said notification must immediately activate the call-out cascade for health emergencies. The Ministry of Health and Wellness National Emergency Operations Centre (MOHW NEOC) should be alerted immediately, via the existing National Epidemiological Surveillance System protocols, to all notifications for COVID-19.

Clusters of visits for respiratory infections or undifferentiated fever must be notified by the medical practitioner (public and private) within 24 hours of suspicion. The local Parish Health Department or National Surveillance Unit must be notified immediately. A Class 1 Notification Form must be submitted within 24 hours of initial notification. Clusters should be investigated and cases in a cluster line listed.

#### Investigation

The Parish Medical Officer (Health) leads the case investigation team and must:

- Initiate case investigation within 24 hours of notification. A preliminary case or cluster investigation report must be submitted within 24 hours of this notification (Appendix 2a).
- Immediately initiate community outbreak control measures, including contact tracing, searching for other cases and line listing of all contacts using the **Contact Tracing Intake** and **Daily Tracking Line Listing** (Appendix 3). Excel spreadsheet provided separately.

#### **Case Follow-up**

The Parish Medical Officer (Health) or designate must ensure the completion of a **Case Follow-up Form** (Appendix 2b). This form will collect data on major events during the course of the illness - including any complications – as well as data on the final disposition of the case, allowing for closure of the case investigation.

#### COVID-19 Convalescent Period Follow-up

The Parish Medical Officer (Health) or designate must ensure the collection of a serum specimen 14 days after recovery. This is done on day 14 post recovery at the COVID-19 Convalescent Period follow-up visit.



### **Contact Tracing**

A contact is a person who experienced any one of the following exposures during the 2 days before and the 14 days after the onset of symptoms of a probable or confirmed case. For confirmed asymptomatic cases, the period of contact is measured as the 2 days before through the 14 days after the date on which the sample was taken which led to confirmation.

All contacts must be listed with the minimum dataset stated in Appendix 3 and 4. Risk assessment must be completed for all contacts.

Contacts are to be classified as follows:

- 1. Face-to-face contact with a probable or confirmed case within 1 meter and for more than 15 minutes
  - a. Bedroom
  - b. Household / Family
  - c. Conveyance travelling in close proximity with (that is, having less than 1 m separation from) a COVID-19 patient in any kind of conveyance
- 2. Direct physical contact with a probable or confirmed case
- 3. Direct care for a patient with probable or confirmed COVID-19 disease without using proper personal protective equipment
- 4. Other situations as indicated by local risk assessments

The completed contact listing should be discussed with the MOHNEOC for a decision to be made regarding the type of quarantine.

- Persons who fall in category 1, 2 or 3 (face-to-face, direct physical contact or direct care for a patient) will be placed in quarantine, and observed daily for the development of symptoms.
- Contacts will be sampled on identification, if they develop symptoms and on day 14 of quarantine if they remain asymptomatic.
- The period of quarantine and observation will end on Day 15 when a negative result for COVID-19 is received.
- All contacts will be given explicit instructions (verbal and written) regarding the steps to be taken if symptoms develop.
- A record of the daily observation checks for contacts should be maintained at the Parish Health Department and daily reports submitted to the MOHNEOC (Appendix 5).



#### C. SURVEILLANCE OF COVID-19 IN HEALTH CARE WORKERS

Health care workers (HCWs) constitute a critical group of persons who are responsible for the management of patients in health care facilities. They also play an important role in ensuring that adequate infection prevention and control (IPC) measures are implemented in healthcare facilities. HCWs are therefore at increased risk for health care associated COVID-19 infection. This document guides the surveillance of COVID-19 in health care workers.

#### Objectives

1. To assess the extent of human-to-human transmission of COVID-19 among health care workers 2. To characterize the range of clinical presentation of infection and the risk factors for infection among health care workers.

3. To evaluate effectiveness of infection prevention and control measures among health care workers

#### Definitions

Health care worker shall be defined for the purposes of COVID-19 surveillance as all staff in the health care facility involved in the provision of care for a COVID-19 infected patient. This includes those who have been present in the same area as the infected patient and those who have not provided direct care to the patient, but who have had contact with the patient's blood or body fluids, contaminated materials or devices and equipment linked to the patient or environmental surfaces.

The cadre of health care workers will therefore include all health care professionals, allied health workers, auxiliary health workers (e.g. cleaning and laundry personnel, x-ray physicians and technicians, clerks, phlebotomists, respiratory therapist, nutritionists, social workers, physical therapists, lab personnel, cleaners, admission/reception clerks, patient transporters, catering staff etc.).

#### **Surveillance Procedures**

Once a COVID-19 infected patient has been identified in a health care facility, a **list of all health** care workers with any exposure to the COVID-19 patient should be prepared (Appendix 6). Check with supervisors and colleagues, duty rosters and the patient's docket and consider all areas of the health care facility that the patient visited.

All health care workers should be interviewed and a HCW COVID-19 **surveillance investigation form** (Appendix 7) completed. If a symptomatic health care worker is too ill to be interviewed, a proxy (colleague or supervisor) may be interviewed and the investigation form completed. The case investigation form for health care workers will be used to collect demographic data, epidemiological data, including clinical symptoms, exposures in health care facility, contact with confirmed case(s) and use of personal protective equipment.



The health care worker is also expected to keep a **log/diary of symptoms** (Appendix 8) experienced daily and report this to the respective Health Department.

#### **Specimen Collection**


Both nasopharyngeal swabs and serum samples should be taken from the HCW based on the following timelines:

#### Nasopharyngeal Swabs

- 1. A nasopharyngeal swab should be taken as soon as the HCW is identified as a possible contact of the confirmed COVID-19 infected patient in the health care facility.
- 2. A second sample should be taken if/ when the HCW becomes symptomatic
- 3. A third sample should be taken at the end of the 14-day quarantine period if the HCW remains asymptomatic.

#### **Serum Samples**

- 1. A serum sample should be taken at identification of the HCW as a possible contact of the confirmed COVID-19 infected patient in the health care facility.
- 2. A second serum sample should be taken at the end of the 14-day quarantine period if the HCW remains asymptomatic.
- 3. A third serum sample should be taken between day 21 and 28 after the collection of the first serum sample regardless of symptoms.





#### Health-Care Worker Surveillance

#### **Health-Care Worker Surveillance**

✓ A Health-Care Worker who presents with a measured fever and a cough/shortness of breath with onset within the last 10 days or less.

This surveillance process is specific to HCWs who are caring for patients and have no known history of contact with a confirmed or probable COVID-19 case.

## SELF OR FACILITY REPORTING

# ACTION: NOTIFY (SELF OR FACILITY REPORT) THE PARISH HEALTH DEPARTMENT AND TAKE A SAMPLE

Please complete Laboratory Form (Appendix 10) and daily SARI / ALRTI / ILI LABORATORY SAMPLE LINE LISTING (Appendix 11 and 12) and submit a copy to the Parish Health Department/National Surveillance Unit (NSU). Ensure the information is as complete as possible. Testing of samples **WILL NOT** be done for samples included on the daily line listing submitted to the NSU.



#### D. MONITORING COMMUNITY TRANSMISSION

#### Severe Acute Respiratory Illness (SARI) Surveillance

✓ A person who presents with symptoms of a measured fever or history of fever and a cough with onset within the last 10 days or less AND who requires hospitalization for their illness.

## ALL HOSPITALS TO REPORT SARI CASES

#### ACTION: NOTIFY THE PARISH HEALTH DEPARTMENT AND TAKE A SAMPLE

Please complete Laboratory Form (Appendix 10) and daily SARI / ALRTI / ILI LABORATORY SAMPLE LINE LISTING (Appendix 11 and 12) and submit a copy to the Parish Health Department/National Surveillance Unit (NSU). Ensure the information is as complete as possible. Testing of samples **WILL NOT** be done for samples included on the daily line listing submitted to the NSU. Daily/Weekly complete Enhanced Hospital SARI / ILI / aLRTI Surveillance Reporting Form (modified Data Collection Form: SARI / ILI Hospitalizations and Death) (Appendix 13).

<u>\*For SARI Sentinel Site</u> – In addition, please continue to report as per Ministry of Health and Wellness, Updated National Surveillance Manual, Section 13, June, 2019.

#### Influenza-Like Illness (ILI) Surveillance

✓ A person who presents with symptoms of a measured fever or history of fever and a cough with onset within the last 10 days or less.

## ALL HEALTH FACILITIES TO REPORT ILI

#### ACTION: NOTIFY THE PARISH HEALTH DEPARTMENT OF TOTAL CASES SEEN WEEKLY AND TAKE SAMPLES OF CASES BASED ON QUOTAS

Please complete Laboratory Form (Appendix 10) and daily SARI / ALRTI / ILI LABORATORY SAMPLE LINE LISTING (Appendix 11 and 12) and submit a copy to the Parish Health Department/National Surveillance Unit (NSU). Ensure the information is as complete as possible. Testing of samples **WILL NOT** be done for samples included on the daily line listing submitted to the NSU.



<u>\*For ILI Sentinel Sites</u> – In addition, please continue to report as per Ministry of Health and Wellness, Updated National Surveillance Manual, Section 13, June, 2019.

#### **Hospital Active Surveillance**

Admitted Lower Respiratory Tract Infection (LRTI) / Pneumonia Surveillance

✓ A Person who presents with a lower respiratory tract infection with onset within the last 14 days or less AND who requires hospitalization for their illness.

## ALL HOSPITALS TO REPORT ADMITTED LRTI / PNEUMONIA

## ACTION: NOTIFY THE PARISH HEALTH DEPARTMENT AND TAKE A SAMPLE

Please complete Laboratory Form (Appendix 10) and daily SARI / ALRTI / ILI LABORATORY SAMPLE LINE LISTING (Appendix 11 and 12) and submit a copy to the Parish Health Department/National Surveillance Unit (NSU). Ensure the information is as complete as possible. Testing of samples **WILL NOT** be done for samples included on the daily line listing submitted to the NSU. Daily/Weekly complete Enhanced Hospital SARI / ILI / aLRTI Surveillance Reporting Form (modified Data Collection Form: SARI / ILI Hospitalizations and Death) (Appendix 13).

#### For All CONFIRMED COVID-19 CASES

Case Investigation & Contact Tracing is to be done. A COVID-19 Case Investigation Form must be completed and submitted to the Parish Health Department/National Surveillance Unit.



## E. SPECIMEN COLLECTION AND TESTING

#### WHO<sup>3</sup> Laboratory Strategy Guideline based on Transmission Scenario

Transmission Scenario:

- Most cases of local transmission linked to chains of transmission

Public Health Aim:

- Stop transmission and prevent spread

Testing Strategy Guidance:

- Test all individuals meeting the suspected case definition
- Consideration in the investigation of cases and clusters of COVID-19
- Clinical management of severe acute respiratory infections when novel coronavirus is suspected
- SARI/ILI surveillance for COVID-19 and reporting

Specimens must be collected from and will be tested for COVID-19 testing for the following persons:

- i. All suspected cases (as per the case definition above)
- ii. All symptomatic contacts of confirmed COVID-19 cases
- iii. All asymptomatic close contacts of confirmed COVID-19 cases
- iv. All SARI cases from ALL Hospitals
- v. All admitted LRTI / Pneumonia from ALL Hospitals
- vi. All ILI Cases
- vii. All health care workers who are contacts of confirmed COVID-19 cases
- viii. All symptomatic health care workers irrespective of contact history

#### Type of specimen

The recommended sample is a lower respiratory tract specimen (e.g., endotracheal aspirate, sputum or bronchoalveolar lavage). These specimens must be placed in a sterile container.

In cases where lower respiratory tract specimens could not be obtained, a nasopharyngeal aspirate (in a sterile container) OR combined nasopharyngeal and oropharyngeal swabs should be taken

<sup>&</sup>lt;sup>3</sup> World Health Organization, 2020 March 22. Laboratory testing strategy recommendations for COVID-19 Retrieved on March 24, 2020 from <u>https://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab\_testing-2020.1-eng.pdf</u>



for testing (Appendix 9). Swabs should be collected with Dacron or polyester flocked swabs and placed in viral transport medium. <u>Avoid using cotton tipped swabs for specimen collection.</u>

For cases with a positive PCR test of a respiratory sample, a **SERUM SAMPLE** (red-top tube) should be taken as follows:

- 1. At confirmation
- 2. Day 14
- 3. Day 21
- 4. Day 14 Post Recovery

#### Labelling of specimens

All specimens must be labeled with:

- 1. Patient Name
- 2. Referring Facility
- 3. Date of Birth
- 4. Diagnosis: Suspected COVID-19
- 5. Date and time of sample collection

Specimens must be placed on ice at 4-8°C and transported **<u>immediately</u>** to the National Public Health Laboratory.

All specimens must be accompanied by a completed Jamaica Laboratory Investigation Form (see attached 5). Contact the Consultant Microbiologist (Tel. No. 876-317-8376) immediately to inform them of the sample.

Samples are <u>NOT</u> to be sent to private laboratories or directly to the University Hospital of the West Indies Laboratory.



## F. DATA ANALYSIS AND INTERPRETATION

Review and analysis of surveillance data must be completed at all levels.

The Parish Medical Officer (Health) must ensure that Class 1 Notification Forms and Case Investigation Forms are forwarded simultaneously to the Regional Health Authorities and the National Surveillance Unit, within the timelines specified above. A line listing of all reported cases should be maintained at the parish health department along with contact listings for each case. Epidemic curves as well as age, sex and geographic distribution of cases must be maintained at the parish level.

The Regional Technical Director, in collaboration with the Regional Medical Epidemiologist, must ensure that the line and contact listings are maintained for each parish. The age, sex, and geographic distribution, as well as the severity of cases should be monitored. Depending on the situation, daily or weekly reports may be required.

The National Epidemiology Unit will conduct analysis of national data, including the epidemiological profile of cases and the epidemic curves as the situation evolves. The National Epidemiology Unit will prepare appropriate reports showing information on the patterns of disease within the population.

#### G. DATA DISSEMINATION AND OUTPUTS

The National Epidemiology will be responsible for forwarding the information obtained from national level analysis to the Ministry of Health and Wellness National Emergency Operations Centre (MOHNEOC).

The National Surveillance Unit will inform the MOHNEOC of any notified, suspected, probable and confirmed cases of novel coronavirus infection immediately upon identification of a suspected, probable, or confirmed case, by providing a minimum data set below.

#### Minimum Dataset for each case

- 1. ID#
- 2. Initials
- 3. Parish
- 4. Classification (Suspected/Confirmed)
- 5. Recent Travel History (Y/N)

- 6. Country of travel
- 7. Contact vs primary case
- 8. Isolated (Y/N)
- 9. Number of secondary cases identified



### **APPENDIX 1: CLASS 1 NOTIFICATION FORM**

#### CLASS 1 REPORTING FORM - INDIVIDUAL NOTIFICATION (ON SUSPICION)

Date of Report: /_	(DD/MM/YY) NEW CASE / PREV	OUSLY REPORTED CASE (Cin	cie One)
Diagnosis:			
Case Demographi	ic Information		
Name (including pet name):		_ Sex: Age:	D.O.B / / (dd/mm/yy)
Address: Lot #:, (Include Landmark)	Street (Name)	Street	(Drive, Road, Close etc)
Community	Neighbouring Community/	District:	Parish:
Workplace/School:			
(H) Phone #:	(Wk) Phone #:	History of overseas travel in par Specify area/country:	
Name of NOK/Parent:		_ Relationship to case:	
Address of NOK/Parent:		Phone No.:	
<b>Clinical Informati</b>	on:		
Symptoms:		Hosp./Facility Name: Medical Record #:	
	/ (dd/mm/yy) Date seen: / / (dd/mm/yy	Case admitted to Hosp?:	Y / N (Circle one)
	Y / N Type:	Date of Admission:	/ (dd/mm/yy)
	(commyy) Laboratory	<ul> <li>Ward:</li> <li>If dead, Date of Death:</li> </ul>	/ (dd/mm/yy)
Notifier Informati	on		
Name of notifier:	Phone #;	Received by MO(H) Parish MO(H) Signature	/ / (dd/mm/yy)
Address: Comments:	Ernan:	Forwarded to R.S.O	/ (dd/mm/yy)
Cardon concretores			Ministry of Health, Surveillance Unit, July 2018



#### **APPENDIX 2a: CASE INVESTIGATION FORM**



#### 2019 Novel Coronavirus (COVID-19) Case Investigation Form

Date of Reporting:	Region:	Parish:	
Doctor:	Hospital / Site:		Ward:
Email:	Pho	ne #:	
Hospital/Medical Record Number:		NEW CASE 🖬	
Last Name:	First Name:		
Date of Birth:	Age:	Sex: MALE 🗖	FEMALE D
Country of Residence:	Parish:	Community	c
Street #: Street Name:		•	

++ Epidemiologic Week of Onset: \_\_\_\_\_ Date of Onset of Illness: \_\_\_\_\_ Admission Date: \_

cpidelinelegie freek er e										
			CLINICAL 2	EPIDEM	IOLOGIC.	AL PRO	11LE			
				CLINICAL	. PROFILI	E				
History of Fever or Fever over 38°	°C (<10 di	igii)				Yes	No	Recorded temperature		*C
Cough	Yes	No	Difficulty Brea	thing/Whe	gnizad	Yes	No	Dyspreal Tachyprea	Yes	No
Rhinomhosa	Yittii	Nó	Nausea//om	ting		Yitti	Nö	Abnormal Lung Auscultations	Yes	No
Sore Throat	Yits	Nó	Headache			Yiel	Nö	Abnormal lung x-ray findings	Yes	No
Shortness of Breath	Yitii	Nó	Myalgia			Yiei	Nö	Seizare	Yes	No
Other, please specify:								Other, please specify:		
				RISK F/	ACTORS					
Pregnancy	Yes	No	Lung Disease	including	COPD	Yes	No	Immunocompromised due to disease or treatment	Yes	No
If yes, Trimester	1 3	2 3	Aathma			Yes	No	HIV/AIDS	Yittili	No
Diabotes Mellitus	Yes	No	Neurological	urological Disease Yes No			Malignancy			
Sickle Cell Disease	Yitii	Nó	Liver Disease	1	Yes No Other, please specify:			Other, please specify:		
Heart Disease	Yes	No	Renal Diseas	a		Yes	No			
			ычо	EMIOLOG	RCAL PR	OFILE				
Occupation Health Care Worker	Heal	th Labo	natory Worker	Working	) with Anir	nala¤	Studer	Other, please specify:		
Close Contact with a person with intection in the 14 days prior to a lifyes, where: HomeO WorkO H	ansat of s	ympton	18 Yos	No	Animal If yes, p				Yes	No
Other, please specify: Close Contect with Probable or the 14 days prior to prest of sym		ed Care			Travel a symptom		n the 1	4 days prior to onset of	Yes	No
If yes, where: Home Work H Other, please specify:	leath Car	e Settir	Yes	No Contact with travelor in past 14 days? If yes, country(ies) visited: Date of departure:				Yes	No	
Visited any Health Facility in the 1 of symptoms If yes, Health Facility visited:	4 days pr	ior to a	Yes	No	Other:					

Ferrer (> 38 °C) may not be present in some patients, such as those who are very young, elderly, immunouppressed, or taking certain medications. Clinical Judgement should be aread to guide testing of patients to such situations. 

A contact is a person: - Providing direct core for Conference (Test Positive) Cases; working with health core workers infected with neural conservation; whiling patients or staying in the same clase environment of a Positive patient; Working together in clase proximity or sharing the same classroom environment with a Test Positive patient - Traveling together with a Test Positive patient to any kind of conveyance; Uning in the same kousehold as a Test Positive patient within a 34-day period after the annet of symptoms in the cure ander consideration.

Prepared by the National Surveillance Unit, Ministry of Health & Wellness

Revised- 2020/01/23

·	□ 45-47 BARBADOS AVENUE □ 24-26 GRENADA CRESCENT □ 10 <sup>A</sup> CHELSEA AVENUE KINGSTON 5, JAMAICA, W.I. Tel: (876) 633-7400/7433/7771/8172/8174
	Website: <u>www.moh.gov.jm</u>

RAVEL HISTORY/ In th	e 14 days before symptom on	set, did the patient:			
Spend time in China?			ΠY		🗆 Unknown
IF Yes,					
Province	City	Departure Date			
Province	City	Departure Date			
Province	City	Departure Date			
Province	City	Departure Date			
Travel to another country (N IF Yes,	ot China)		ΠY		🗆 Unknown
Province/State	City				
Province/State	City	Departure Date			
Province/State	City	Departure Date			
Have close contact <sup>2</sup> with a p	erson who is under investigation to	r 2019-aCoV?	ΠY		🗆 Unknown
Have close contact <sup>2</sup> with a p	erson with laboratory confirmed 20	19-nCaV7	ΠY	$\square$ N	Unknown
Was the case ill at the tir Is the case a Jamaican	case?	ae?			Unknown Unknown Unknown Unknown
Is the case an internation In which country wa	nal case? Is the case diaphosed with 2019 n-	CoV?	ΠY	$\square$ N	🗆 Unknown

Sample taken: Yes 🗖	No 🗖 Sample Type: _	Date Sample Taken:						
Sample taken to Lab:		Date Sample Taken	to La	b:				
Laboratory Results:	Virology Positive 🗖	Negative	Virus:					
-	Bacteriology Positive 🗖	Negative	Bacteria:					
Treatment Received:					Patient ventilated 🗖			
Isolated 🗖	Date:		Admission to ICU		Date:			
Discharged from Ho	spital 🗖 Date:		Death 🗖		Date:			
Final Diagnosis:			MO(H) Signature:					

Fever (> 38 <sup>1</sup>C) may not be present in some patients, such an those who are very young, elderly, knownouppressed, or taking certain medications. Clinical judgement should be areal to guide testing of patients to such situations

A contact is a person: - Providing direct core for Confermed (Text Positive) Cases; working with health core workers infected with neural concountry; whiling patients or staying to the same class environment of a Positive patient; Working together in class proximity or sharing the same classroom environment with a Text Positive patient - Traveling together with a Text Positive patient is any kind of convegance; Using in the same household as a Text Positive patient within a 34-day period after the annet of symptoms in the case ander consideration.

Prepared by the National Surveillance Unit, Ministry of Health & Wellness

Revised- 2020/01/23



#### **APPENDIX 2b: CASE FOLLOW-UP FORM**



#### 2019 Novel Coronavirus (COVID-19) Case Follow-up Form

Date of Reporting:	Region:	Parish:	
Date of Reporting: Doctor:	Hospital / Site:		Ward:
Email:		Phone #:	

Hospital/Medical Record Number:		
Last Name:	First Nar	ne:
Date of Birth:	Age:	\$ex: MALE D FEMALE D
Country of Residence:	Parish:	Community:

Epidemiologic Week of Onset: Date of Onset of Illness:

	CLINICAL & EPIDEMIOLOGICAL PROFILE									
CURRENT STATUS Max. Recorded temperature*C										
Recovered D Dete		SYMPTOMSISIONS								
Silil C		Cough	Yes	No	Headache	Yes	No			
Diad D Date		Son throat	Yes	No	Nazsoa	Yés	Nó			
Unknown D Date		Runny nase	Yes	No	Vomiting	Yes	No			
CIRCIDIES DI DIGI		Shortness of Breath	Yes	No	Rash	Yes	No			
CONFLICATIONS		Agousia	Yes	No	Conjunctivitis	Yes	No			
Acute Respiratory Distrass Syndrame	Data	Anasmia	Yes	No	Seizares	Yes	No			
Acuto Ronal Failuro 🗆	Data	Fatigue	Yes	No	Altered consciousness	Yes	No			
Cardiac Failure 🛛	Data	Joint Pain	Yes	No	Novebland	Yes	No			
Consumptive Cosquiopathy	Data	Masch Pain	Yes	No	Other signa/symptoms (specify)					
Pneumonia by cheat X- ray	Date	Chills	Yes	No	Other signa/symptoms (specify)					

Admitted to ICU: Yes > No > If Yes, Date admitted to ICU: \_\_\_\_\_ Date Discharged from ICU: \_\_\_\_\_

Mechanical Ventilation: Yes 
No 
If Yes, Date started: \_\_\_\_\_ Date stopped: \_\_\_\_\_

Length of Ventilation (days): \_\_\_\_\_ Extracorporeal Membrane Oxygenation: Yes D No D

Admission Date:

**DAY 21** 

	LABORATORY DATA									
	MOLECULAR TESTING									
Sample Type	Collection Date	lest lype	Results	Result Date						
Nasopharyngoal 🗆	Data	PCR D Other	COVID-19 +ve COVID-19 -ve COVER+ve C							
Oropharyngeal	Data	PCR D Other	PCR D Other COVID-19 +vs D COVID-19 -vs D Other+vs D							
Sputam 🗆	Data	PCR D Other	COVID-19 +ve COVID-19 -ve COVID-19 -ve COVID-19 =ve							
Other (specify)										
		SEROLOGICA	AL TESTING							
Sample Type	Collection Date	leat lype	Results	Result Date						
Serum D	D atta	IgM 🖸	Pastin C The							
Other (specify)		tgG D	Negative D							
		Other (ispecify)	Inconclusive 🗅							

MO(H) Signature:

Date:

Recovered - A patient is considered recovered from COVID-19 after two successive negative RT-PCR tests.

National Surveillance Unit, Ministry of Health & Wellness Instrumentation



#### **APPENDIX 3: FIELDS FOR CONTACT INTAKE LINE LISTING**

- i. Date of intake
- ii. Name of Suspected/Confirmed Case
- iii. Type of Contact
- iv. Risk level
- v. Date of most recent contact
- vi. First name
- vii. Last name
- viii. Date of Birth
- ix. Current Age
- x. Sex at Birth
- xi. Current Age
- xii. Telephone number 1
- xiii. Next of Kin name
- xiv. Next of Kin telephone number
- xv. GPS Coordinates
- xvi. Street Number
- xvii. Street Name
- xviii. District
- xix. Community
- xx. Parish
- xxi. Landmark
- xxii. Symptomatic/Asymptomatic
- xxiii. Date of onset of symptoms
- xxiv. Fever (Y/N)
- xxv. Cough (Y/N)
- xxvi. Shortness of breath (Y/N)
- xxvii. Other, specify
- xxviii. Comments



# APPENDIX 4: FIELDS FOR CONTACT TRACING DAILY TRACKING LINE LISTING

- i. Date of assessment
- ii. Time of assessment
- iii. Parish
- iv. First Name
- v. Last Name
- vi. Day 1
- vii. Day 2
- viii. Day 3
- ix. Day 4
- x. Day 5
- xi. Day 6
- xii. Day 7
- xiii. Day 8
- xiv. Day 9
- xv. Day 10
- xvi. Day 11
- xvii. Day 12
- .... Day 12
- xviii. Day 13
- xix. Day 14
- xx. Remarks



#### PARISH DAILY CONTACT TRACING SURVEILLANCE REPORTING FORM

Parish: \_\_\_\_\_

Date of Report: \_\_\_\_\_

## **CONTACT TRACING SUMMARY REPORT**

CONFIRMED CASE'S INITIALS	Total No. of Households visited (cum)	Total No. of Overall Contacts Identified	Total No. of Community Contacts Identified	Total No. of Community Contacts Currently being Followed	Total No. of Close Contacts Identified	Total No. of Close Contacts Ever Followed	Total No. of Close Contact Currently being Followed	Total No. of contacts currently symptomatic	Total No. of contacts currently isolated

Report Prepared by: \_\_\_\_\_

Position of Reporter:

Parish MO(H) signature:

Revised April 15, 2020. V17



### APPENDIX 6: HEALTH CARE WORKER LINE LISTING TEMPLATE

Name of COVID-19 positive patient	Name of HCW contact	Age	Sex	Occupation/ job title	Type of exposure	Risk category (high/ low)	Date of first contact	Date of last contact



□ RKA Building, 10-16 Grenada Way □ 45-47 Barbados Avenue □ 24-26 Grenada Crescent □ 10<sup>A</sup> Chelsea Avenue KINGSTON 5, JAMAICA, W.I. Tel: (876) 633-7400/7433/7771/8172/8174 Website: www.moh.gov.jm

# APPENDIX 7: HEALTH CARE WORKER SURVEILLANCE CASE INVESTIGATION FORM

#### Health Care Worker Surveillance Case Investigation Form

Contact Identifier Information				
First name: Su	irname:			
Sex  Male Female Not known D	ate of Birth (I	DD/M M /YYYY)//		
Age (years, months)				
Email	elephone nun	nber:		
Address:				
Parish:				
	Yes D No			
Occupation in health care facility	Nutritionist	s/dietitians		
		h care provider:		
	Lab person			
		reception clerks		
	Patient tran	sporters		
Radiology / x-ray technician	Catering sta	off		
Phlebotomists	Cleaners			
Physical theranists				
Infection prevention and control measures information				
What date was your most recent IPC training within the h	nealth	DD/MM/YYYY		
care facility? (DD/MM/YYYY)				
How much cumulative IPC training (standard precautions		Less than 2 hours		
additional precautions) have you had at this health care f	acility?	More than 2 hours		
Do you follow recommended hand hygiene practices?				
Always, as recommended	casionally 🗆	Rarely		
Do you use alcohol-based hand rub or soap and water be	fore touchin	g a patient?		
Always, as recommended	casionally 🗆	Rarely		
Do you use alcohol-based hand rub or soap and water be	fore cleaning	z/aseptic procedures?		
Always, as recommended D Most of the time D Oct				
Do you use alcohol-based hand rub or soap and water aft		r		
Always, as recommended Always, as recommended October Most of the time October October O	. ,	, , ,		
	,	,		
Do you use alcohol-based hand rub or soap and water aft	~	-		
Always, as recommended	casionally	Rarely		
Do you use alcohol-based hand rub or soap and water aft	ter touching a	a patient's surroundings?		
Always, as recommended	casionally 🗆	Rarely		
Do you follow IPC standard precautions when in contact	with any pati	ient?		
Always, as recommended	casionally 🗆	Rarely I don't know what IPC standard		
precautions are				
Do you wear PPE when indicated?		<ul> <li>Always, according to the risk assessment</li> </ul>		
PPE includes: Medical mask, Face shield, Gloves,		<ul> <li>Most of the time, according to the risk</li> </ul>		
Goggles/glasses, Gown, Coverall, Head cover, Respirator		assessment		
N95 or equivalent), Shoe covers)		Occasionally		
		Rarely		
Is PPE available in sufficient quantity in the health care fa	cility?	Yes   No   Unknown		
Exposures to COVID-19 infected patient				
Date of admission of 2019-nCoV confirmed patient		DD/MM/YYYY:		
(DD/MM/YYYY)				



	act (within 1 meter) wit	in the patien	t since his/her admission?					
n Yes in Noir Unknown								
<ul> <li>If yes, how man</li> </ul>	y times (total)?							
- If yes, for how l	ong each time? 🗆 <5 i	minutes c	5-15 minutes D>15 minutes	6				
<ul> <li>If yes, did you have prolonged face-to-face exposure</li> </ul>								
(>15 minutes)?	D Yes D No D Un	known						
If yes, did you wear PPE?	Yes O No D Ur	nknown						
, , ,		A						
If yes, what type? Tick all	that apply:							
Medical mask	Face shield	Gloves	Goggles/glasses	🗆 Gown				
Coverall	Head cover	Respirat	or (e.g. N95 or equivalent)	Shoe covers				
<ul> <li>If you were wea</li> </ul>	aring a medical mask, wi	hat type:						
<ul> <li>If you were wea</li> </ul>	aring a respirator, was it	test fitted?	Yes      No     Unknown					
<ul> <li>If you were wear</li> </ul>	aring gloves, did you ren	nove	🗆 Yes 🗆 No					
gloves after con	ntact with the patient?							
<ul> <li>If yes, did you p</li> </ul>	erform hand hygiene be	efore contac	t with the patient?					
Always, as recommended			-					
If yes:		in occasi	onally is reality					
Alcohol-based hand ru	b 🗆 Soap and water	Water						
<ul> <li>If yes, did you p</li> </ul>	erform hand hygiene af	fter contact :	with the patient?					
Always, as recommend	ied 🛛 🗆 Most of the tim	e 🗉 Occasi	onally Barely					
If yes:								
Alcohol-based hand ru	b Soap and water	Water						
<ul> <li>If yes, were you</li> </ul>	present for any aeroso	lizing proces	lures performed on the patient?					
🗆 Yes 🗆 No 🗆	Unknown							
If yes, describe the proce	edure:							
If yes, did you wear PPE?	' 🗆 Yes 🗆 No 🗆 Unknow	n						
If yes, what type? Tick al								
Medical mask	Face shield	Gloves	Goggles/glasses	Gown				
			□ Goggles/glasses for (e.g. N95 or equivalent)	□ Gown □ Shoe covers				
Medical mask     Coverall	Face shield     Head cover	Respirat	or (e.g. N95 or equivalent)	Shoe covers				
<ul> <li>Medical mask</li> <li>Coverall</li> <li>If yes, did you compared to the second second</li></ul>	Face shield     Head cover	Respirat	or (e.g. N95 or equivalent)	Shoe covers				
Medical mask     Coverall	Face shield     Head cover	Respirat	or (e.g. N95 or equivalent)	Shoe covers				
<ul> <li>Medical mask</li> <li>Coverall</li> <li>If yes, did you could be a set of the set of the</li></ul>	Face shield     Head cover ome into contact with t	Respirat the patient's	or (e.g. N95 or equivalent)	Shoe covers				
<ul> <li>Medical mask</li> <li>Coverall</li> <li>If yes, did you could be a set of the set of the</li></ul>	PPE? Yes No	Respirat the patient's	or (e.g. N95 or equivalent)	Shoe covers				
<ul> <li>Medical mask</li> <li>Coverall</li> <li>If yes, did you of If yes, which body fluids:</li> <li>If yes, were you wearing If yes, what type? Tick all</li> </ul>	PPE? Yes No  I that apply:	Respirat	tor (e.g. N95 or equivalent) body fluids?	□ Shoe covers Jnknown				
<ul> <li>Medical mask</li> <li>Coverall</li> <li>If yes, did you co If yes, which body fluids:</li> <li>If yes, were you wearing If yes, what type? Tick al Medical mask</li> </ul>	PPE? Yes No	Respirat     Respirat     Unknown     Gloves	or {e.g. N95 or equivalent} body fluids? □ Yes □ No □ U □ Goggles/glasses	Shoe covers  Inknown  Gown				
<ul> <li>Medical mask</li> <li>Coverall</li> <li>If yes, did you co If yes, which body fluids:</li> <li>If yes, were you wearing If yes, what type? Tick al</li> <li>Medical mask</li> <li>Coverall</li> </ul>	Face shield     Head cover  me into contact with t  PPE? Yes No  I that apply:     Face shield     Head cover	Respirat Respirat Unknown Gloves Respirat	or (e.g. N95 or equivalent) body fluids? □ Yes □ No □ U □ Goggles/glasses tor (e.g. N95 or equivalent)	Shoe covers  Inknown      Gown      Shoe covers				
<ul> <li>Medical mask</li> <li>Coverall</li> <li>If yes, did you co If yes, which body fluids:</li> <li>If yes, were you wearing If yes, what type? Tick al</li> <li>Medical mask</li> <li>Coverall</li> <li>Have you had direct control</li> </ul>	Face shield     Head cover      me into contact with t      PPE?     Yes     No      I that apply:     Face shield     Head cover  tact with the patient's n	Respirat     Respirat     Unknown     Gloves     Respirat materials sino	or (e.g. N95 or equivalent) body fluids? □ Yes □ No □ U □ Goggles/glasses tor (e.g. N95 or equivalent) te his/her admission? □ Yes □	Gown Gown Shoe covers No  Unknown				
<ul> <li>Medical mask</li> <li>Coverall</li> <li>If yes, did you co If yes, which body fluids:</li> <li>If yes, were you wearing If yes, what type? Tick al</li> <li>Medical mask</li> <li>Coverall</li> <li>Have you had direct control</li> </ul>	Face shield     Head cover      me into contact with t      PPE?     Yes     No      I that apply:     Face shield     Head cover  tact with the patient's n	Respirat     Respirat     Unknown     Gloves     Respirat materials sino	or (e.g. N95 or equivalent) body fluids? □ Yes □ No □ U □ Goggles/glasses tor (e.g. N95 or equivalent)	Gown Gown Shoe covers No  Unknown				
<ul> <li>Medical mask</li> <li>Coverall</li> <li>If yes, did you of If yes, which body fluids:</li> <li>If yes, were you wearing If yes, what type? Tick al</li> <li>Medical mask</li> <li>Coverall</li> <li>Have you had direct cont Patient's materials: personal</li> </ul>	Face shield     Head cover      me into contact with t      PPE?     Yes     No      I that apply:     Face shield     Head cover  tact with the patient's n	Respirat Che patient's Unknown Gloves Respirat materials sing and medical e	or (e.g. N95 or equivalent) body fluids? □ Yes □ No □ U □ Goggles/glasses tor (e.g. N95 or equivalent) te his/her admission? □ Yes □	Gown Gown Shoe covers No  Unknown				
<ul> <li>Medical mask</li> <li>Coverall</li> <li>If yes, did you co If yes, which body fluids:</li> <li>If yes, were you wearing If yes, what type? Tick al</li> <li>Medical mask</li> <li>Coverall</li> <li>Have you had direct com Patient's materials: personal If yes, which mage</li> </ul>	Face shield     Head cover      Mead cover      PPE?     Yes     No      I that apply:     Face shield     Head cover  tact with the patient's n onal belongings, linen a	Respirat the patient's Unknown Gloves Respirat materials sing md medical e oply:	or (e.g. N95 or equivalent) body fluids? □ Yes □ No □ U □ Goggles/glasses tor (e.g. N95 or equivalent) te his/her admission? □ Yes □	Shoe covers Inknown Gown Shoe covers No  Unknown have had contact with				
<ul> <li>Medical mask</li> <li>Coverall</li> <li>If yes, did you co If yes, which body fluids:</li> <li>If yes, were you wearing If yes, what type? Tick al</li> <li>Medical mask</li> <li>Coverall</li> <li>Have you had direct com Patient's materials: personal If yes, which mage</li> </ul>	Face shield     Head cover      me into contact with t      PPE? Yes No      I that apply:     Face shield     Head cover      tact with the patient's n     onal belongings, linen a     sterials? Tick all that ap     nal items Liner	Respirat Che patient's Unknown Gloves Respirat materials since and medical e oply: n Med	Goggles/glasses for (e.g. N95 or equivalent) Goggles/glasses for (e.g. N95 or equivalent) the his/her admission? Yes a equipment that the patient may ical devices used on the patient	Shoe covers Inknown Gown Shoe covers No  Unknown have had contact with				
<ul> <li>Medical mask</li> <li>Coverall</li> <li>If yes, did you of If yes, which body fluids:</li> <li>If yes, what type? Tick al</li> <li>Medical mask</li> <li>Coverall</li> <li>Have you had direct com Patient's materials: person</li> <li>If yes, which materials</li> <li>Clothes</li> <li>Person</li> </ul>	Face shield     Head cover      me into contact with t      PPE? Yes No      I that apply:     Face shield     Head cover      tact with the patient's n     onal belongings, linen a     sterials? Tick all that ap     nal items Liner	Respirat Che patient's Unknown Gloves Respirat materials since and medical e oply: n Med	Goggles/glasses for (e.g. N95 or equivalent) Goggles/glasses for (e.g. N95 or equivalent) the his/her admission? Yes a equipment that the patient may ical devices used on the patient	Shoe covers Inknown Gown Shoe covers No  Unknown have had contact with				
<ul> <li>Medical mask</li> <li>Coverall</li> <li>If yes, did you of If yes, which body fluids:</li> <li>If yes, were you wearing If yes, what type? Tick al</li> <li>Medical mask</li> <li>Coverall</li> <li>Have you had direct cont Patient's materials: perso</li> <li>If yes, which ma</li> <li>Clothes</li> <li>Perso</li> <li>Medical equipment co</li> <li>Other:</li> </ul>	Face shield     Head cover      me into contact with t      PPE? Yes No      I that apply:     Face shield     Head cover      tact with the patient's n     onal belongings, linen a     sterials? Tick all that ap     nal items Liner	Respirat Che patient's Unknown Gloves Respirat materials sing medical e oply: n Med (e.g. ventilat	Goggles/glasses for (e.g. N95 or equivalent) Goggles/glasses for (e.g. N95 or equivalent) the his/her admission? Yes a equipment that the patient may ical devices used on the patient	Shoe covers Inknown Gown Shoe covers No  Unknown have had contact with				

□ RKA Building, 10-16 Grenada Way □ 45-47 Barbados Avenue □ 24-26 Grenada Crescent □ 10<sup>A</sup> Chelsea Avenue KINGSTON 5, JAMAICA, W.I. Tel: (876) 633-7400/7433/7771/8172/8174 Website: www.moh.gov.jm

Sore throat	0		0		
Symptom	Yes	No	Unknown	If Yes, date (DD/MM/YYYY):/_	_/
Respiratory symptoms					
				If yes, specify maximum temperat	ure:
Fever (238 °C) or history of fever				Yes  No  Unknown	
Date of first symptom onset (DD/	MM/Y	(11)		(DD/MM/YYYY)/_/ Asymptomatic DUnknown	
period since the patient has been a			es 🗆 No	If no, please skip symptoms section	IS
lave you experienced any respirat	ory syn	nptoms	(sore throat	, cough, running nose, shortness of	breath) in the
Exposures to COVID-19 infected p	atient				
If yes: Alcohol-based hand rub	□ S	ioap an	d water 🗆	Water	
- If yes, did you perform ha	and hy	giene al		vith these surfaces?   Yes  No	
Coverall     Head				or (e.g. N95 or equivalent)	Shoe covers
If yes, what type? Tick all that app Medical mask Effects Face			a Gloves	Goggles/glasses	n Gown
If yes, were you wearing PPE?	Yes 🗆	Noni	lakaowa		
If yes, which body fluids:	'n				
<ul> <li>If yes, did you come into</li> <li>Yes          No              Unknow     </li> </ul>		t with t	the patient's	body fluids via the surfaces around	the patient?
<ul> <li>How many times since hi</li> </ul>			· ·		
🗆 Other:					One bance
<ul> <li>If yes, which surfaces? T</li> <li>Red. B Pathroom, B Ward co.</li> </ul>			-	Bedside table Dining table	Madical and panel
Have you had direct contact with			-	tient?	
If yes:			p and water	Water	
<ul> <li>If yes, did you perform have a second second</li></ul>		-		vith the patient's materials? onally	
,		,	·		
<ul> <li>If yes:          <ul> <li>Alcohol-based hand rub</li> <li>If you were wearing glow</li> </ul> </li> </ul>				Water	Yes 🗆 No
<ul> <li>If yes, did you perform have a second second</li></ul>		~		t with the patient's materials? onally	
Coverall     General				or (e.g. N95 or equivalent)	Shoe covers
Medical mask     Face			Gloves	Goggles/glasses	Gown
If yes, what type? Tick all that app	ily:				
If yes, were you wearing PPE?	🗆 Yes	n No n	Unknown		
If yes, which body fluids:					
a Yes D No	5		D Un	known	
<ul> <li>If yes, did you come into c</li> </ul>	ontact	with th		ody fluids via the patient's material	s?
			1		



#### □ RKA Building, 10-16 Grenada Way □ 45-47 Barbados Avenue □ 24-26 Grenada Crescent □ 10<sup>A</sup> Chelsea Avenue KINGSTON 5, JAMAICA, W.I. Tel: (876) 633-7400/7433/7771/8172/8174 Website: <u>www.moh.gov.jm</u>

Cough							
Runny nose							
Shortness of breath							
Other symptoms							
Symptom	Yes	No	Unknown	Symptom	Yes	No	Unknown
Chills				Muscle aches			
Vomiting				Joint ache			•
Nausea	0		0	Loss of appetite			
Diarrhoea				Nose bleed			
Headache			0	Fatigue			
Rash				General malaise			
Conjunctivitis		0		Other symptoms, specify			
Health care worker pre-existing	conditi	on(s)					
Condition	Yes	No	Unknown	Condition	Yes	No	Unknown
Obesity				Chronic liver disease			
Cancer				Chronic kidney disease		0	
Diabetes	0			Heart disease			
HIV/other immune deficiency	0	D	•	Chronic neurological impairment/disease		0	0
Asthma (requiring medication)				Chronic haematological disorders			
Chronic lung disease (non- asthma)				Organ or bone narrow recipient			
Other pre-existing condition(s)				Specify			
Pregnancy				If yes, specify trimester: Estimated delivery date (D			n NA
Contact specimen collection (Day	(1)						
las baseline serum been taken?				🗆 Yes 🗆 No 🗆 Unknown			
				If yes, specify date (DD/M)	и/YYYY);		
Which laboratory was the specin	en sen	t to?					
Date sent to laboratory (DD/MM	MMM 1			1 1			



### **APPENDIX 8: HEALTH CARE WORKER SYMPTOM DIARY**

Day		Symptoms													
	No symptoms (check if none experienced)	Fever ≥38°C	Sore throat	Cough	Runny nose	Shortness of breath	Other symptoms: specify								
0	🗆 None	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No									
1	🗆 None	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No									
2	□ None	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No									
3	🗆 None	🗆 Yes 🗆 No	□ Yes □ No	□ Yes □ No	□ Yes □ No	🗆 Yes 🗆 No									
4	🗆 None	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No									
6	🗆 None	🗆 Yes 🗆 No	□ Yes □ No	🗆 Yes 🗆 No	□ Yes □ No	🗆 Yes 🗆 No									
7	None	🗆 Yes 🗆 No	□ Yes □ No	□ Yes □ No	□ Yes □ No	□ Yes □ No									
8	None	🗆 Yes 🗆 No	□ Yes □ No	□ Yes □ No	□ Yes □ No	□ Yes □ No									
9	🗆 None	🗆 Yes 🗆 No	□ Yes □ No	🗆 Yes 🗆 No	□ Yes □ No	🗆 Yes 🗆 No									
10	□ None	🗆 Yes 🗆 No	□ Yes □ No	□ Yes □ No	□ Yes □ No	□ Yes □ No									
11	□ None	🗆 Yes 🗆 No	□ Yes □ No	□ Yes □ No	□ Yes □ No	□ Yes □ No									
12	🗆 None	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No									
13	🗆 None	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	□ Yes □ No	🗆 Yes 🗆 No									
14	🗆 None	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No									
15	🗆 None	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No									
16	🗆 None	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No									
17	🗆 None	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No									
18	□ None	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No									
19	□ None	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No									
20	🗆 None	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No									
21	🗆 None	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No	🗆 Yes 🗆 No									

Revised April 15, 2020. V17



## APPENDIX 9: TAKING A NASOPHARYNGEAL SAMPLE

	TAKING A NASOPHARYNGEAL SWAB								
	Ensure adherence to airborne precautions								
<ul> <li>Assemble eq</li> </ul>	juipment and forms								
	RESOURCES NEEDED								
	Viral or Universal Transport Medium								
	Synthetic swabs								
	Lab Investigation Form								
	Gown, N95 respirator, Eye Protection, Gloves								
<ul> <li>Wash hands;</li> <li>Have the patent's</li> <li>Tilt patient's</li> <li>Insert swab i</li> <li>Leave swab i</li> <li>Slowly removes</li> <li>Place tip of s</li> <li>Break/Cut of</li> <li>Seal the capes</li> </ul>	sal Transport Medium or Viral Transport Medium (VTM) tube ; put on gown, N95 respirator, eye protection, and gloves tient evacuate mucous (if present) from both nostrils head back 70 degrees into nostril (to a depth equal to distance from nostrils to outer opening of the ears) in place for several seconds to absorb secretions ve swab while rotating it – swab both nostrils with the same swab swab into the sterile UTM/VTM tube below the level of the liquid media. If the applicator stick at the scored point or to a length that allows it to fit the tube tightly on the UTM/VTM tube /TM tube on frozen cold pack								




# APPENDIX 10: JAMAICA: LABORATORY SURVEILLANCE INVESTIGATION FORM

	Patient Information		5. Case/S					
Las	t Name		□ Single ca		A			Unknown
	t Name		6. Date of 0	Onset of I	lness	7. Oute Hospitali Died?	zed?	
			8. Signs a	and Sympt	oms	Died.	8	
	nder 🗆 M 🗆 F Age 📃 🗆	years 🗆 months				→ (	Onset:	YYYYMMDD.
Dat	e of Birth <u>YYYYMM/DD</u>							YYYYMMDD
	et <u>##</u>		□ Pain →					
	(Parish		□ Haemorr	10.000	Service and the second second	scribe		
	tal Code Tel:			1.24		and the second second	Oncot	2000MMM200
Tra	vel History DY DN Country Visite	ed:	Altered me				and the	onic Conditions
Con Atte Sigr Rep Tel:	Referring Doctor isultant: inding Dr.: inding Dr.: indure: iorting Address: Fax: Specimen Taken:	/ WARD	Chilis Circulatory Conjunctiv Convulsion Coryza Cough Diarrhoea Failure to 1	ittis ns	Lympha     Kernig's     Vomiting	ffness denopathy sign } ss of limbs oss		sthma utoimmune disease ancer labetes Meilitus IV / AIDS
			Fever &     Fever (ui			Fever &	Neurol	logic
ipec lam Vhei	ood/Animal/Environment Samp imen ID e of food/env sample re specimen(s) collected utbreak		BCG: DYD DPT: DYD HBV: DYD MMR: DYD			MR: D Pollo: D YF: D		N / /
ipec lam Vhei 0	imen ID e of food/env sample re specimen(s) collected utbreakTracebackSurv	ey 🗆 Other	BCG: DYD DPT: DYD HBV: DYD MMR: DYD <sup>†</sup> Spedfy		$\frac{I}{I} \frac{I}{I}$ $\frac{I}{I} \frac{I}{I}$	MR: Polio: YF: Other <sup>4</sup> :		
ipec lam Vhei 0	imen ID e of food/env sample re specimen(s) collected	ey 🗌 Other Sputum; CSF; Sweb;	BCG: DYE DPT: DYE HBV: DYE MMR: DYE <sup>‡</sup> Specity Urine; Stool; Tice	□ N □ N □ N □ N □ N □ U Sue; Placma	/ / / / / / / / /	MR: Polio: YF: Other <sup>4</sup> : Water;Anima		N// N// N// N// Domment; if other spec
ipec lam Vhei 0	imen ID e of food/env sample re specimen(s) collected utbreak	ey 🗆 Other	BCG: DYE DPT: DYE HBV: DYE MMR: DYE <sup>‡</sup> Specity Urine; Stool; Tice	□ N □ N □ N □ N □ N □ U Sue; Placma	$\frac{I}{I} \frac{I}{I}$ $\frac{I}{I} \frac{I}{I}$	MR: Polio: YF: Other <sup>4</sup> : Water;Anima		
ipec lam Vhei 0	imen ID e of food/env sample re specimen(s) collected utbreakTracebackSurv	ey 🗌 Other Sputum; CSF; Sweb;	BCG: DYE DPT: DYE HBV: DYE MMR: DYE <sup>‡</sup> Specity Urine; Stool; Tice	□ N □ N □ N □ N □ N □ U Sue; Placma	/ / / / / / / / /	MR: Polio: YF: Other <sup>4</sup> : Water;Anima		N/ / / / / / / / / / / / / / / / /
peo lam /hei ] O	imen ID e of food/env sample re specimen(s) collected utbreak	ey 🗌 Other Sputum; CSF; Sweb;	BCG: DYE DPT: DYE HBV: DYE MMR: DYE <sup>‡</sup> Specity Urine; Stool; Tice	□ N □ N □ N □ N □ N □ U Sue; Placma	/ / / / / / / / /	MR: Polio: YF: Other <sup>4</sup> : Water;Anima		N/ / / / / / / / / / / / / / / / /
peo lam /hei ] O	imen ID e of food/env sample re specimen(s) collected utbreak	ey 🗌 Other Sputum; CSF; Sweb;	BCG: DYE DPT: DYE HBV: DYE MMR: DYE <sup>‡</sup> Specity Urine; Stool; Tice	□ N □ N □ N □ N □ N □ U Sue; Placma	/ / / / / / / / /	MR: Polio: YF: Other <sup>4</sup> : Water;Anima		N/ / / / / / / / / / / / / / / / /
peo lam /hei ] O	imen IDe of food/env sample re specimen(s) collected utbreak	ey 🗌 Other Sputum; CSF; Sweb;	BCG: DYE DPT: DYE HBV: DYE MMR: DYE <sup>‡</sup> Specity Urine; Stool; Tice	□ N □ N □ N □ N □ N □ U Sue; Placma	/ / / / / / / / /	MR: Polio: YF: Other <sup>4</sup> : Water;Anima		N/ / / / / / / / / / / / / / / / /
ipec lam Vhei 0	imen IDe of food/env sample re specimen(s) collected utbreak	ey 🗌 Other Sputum; CSF; Sweb;	BCG: DYE DPT: DYE HBV: DYE MMR: DYE <sup>‡</sup> Specity Urine; Stool; Tice	□ N □ N □ N □ N □ N □ U Sue; Placma	/ / / / / / / / /	MR: Polio: YF: Other <sup>4</sup> : Water;Anima		N/ / / / / / / / / / / / / / / / /
ipec Iam Vhe	imen IDe of food/env sample re specimen(s) collected utbreak Traceback Surv *&erum EDTA blood; Blood eneer; *Type of Specimen Date Specimen Collected Lab Test(s) Requested Date Received at Nat Lab Nat Lab Specimen ID	ey 🗌 Other Sputum; CSF; Sweb;	BCG: DYE DPT: DYE HBV: DYE MMR: DYE <sup>‡</sup> Specity Urine; Stool; Tice	□ N □ N □ N □ N □ N □ U Sue; Placma	/ / / / / / / / /	MR: Polio: YF: Other <sup>4</sup> : Water;Anima		N/ / / / / / / / / / / / / / / / /
ipec lam Vhei 0	imen IDe of food/env sample re specimen(s) collected utbreak	ey 🗌 Other Sputum; CSF; Sweb;	BCG: DYE DPT: DYE HBV: DYE MMR: DYE <sup>‡</sup> Specity Urine; Stool; Tice	□ N □ N □ N □ N □ N □ U Sue; Placma	/ / / / / / / / /	MR: Polio: YF: Other <sup>4</sup> : Water;Anima		N/ / / / / / / / / / / / / / / / /
ipec lam Vhei 0	imen IDe of food/env sample re specimen(s) collected utbreak	ey 🗌 Other Sputum; CSF; Sweb;	BCG: DYE DPT: DYE HBV: DYE MMR: DYE <sup>‡</sup> Specity Urine; Stool; Tice	□ N □ N □ N □ N □ N □ U Sue; Placma	/ / / / / / / / /	MR: Polio: YF: Other <sup>4</sup> : Water;Anima		N/ / / / / / / / / / / / / / / / /
ipec lam Vhei 0	imen IDe of food/env sample re specimen(s) collected utbreak	ey 🗌 Other Sputum; CSF; Sweb;	BCG: DYE DPT: DYE HBV: DYE MMR: DYE <sup>‡</sup> Specity Urine; Stool; Tice	□ N □ N □ N □ N □ N □ U Sue; Placma	/ / / / / / / / /	MR: Polio: YF: Other <sup>4</sup> : Water;Anima		N/ / / / / / / / / / / / / / / / /
peo (much	imen IDe of food/env sample re specimen(s) collected utbreak	ey D Other	BCG: UY I DPT: UY I HBV: UY I *Spedy_ Urine; Btool; Tiec n 1	N     N     N     N     N     N     N     N     Sue; Placma	(PPT); Food; Specimen 2	MR: Polio: Polio: Otherf: Otherf: Water; Anima 2		N/ / / / / / / / / / / / / / / / /



# APPENDIX 11: ENHANCED RESPIRATORY INFECTION SURVEILLANCE REPORTING REQUIREMENTS FLOW CHART



Revised April 15, 2020. V17

Page **30** of **32** 



### APPENDIX 12: SARI / ALRTI / ILI LABORATORY SAMPLE LINE LISTING

Pa	arish:		Institu	ıtion:		Date of Reporting:				
Classification Type (SARI / ILI / aLRTI)	Name	Age	Sex (M/F)	Address	Community	Parish	Travel History (Yes/No)		Date of Onset of Symptoms	Symptoms



#### □ RKA Building, 10-16 Grenada Way □ 45-47 Barbados Avenue □ 24-26 Grenada Crescent □ 10<sup>A</sup> Chelsea Avenue KINGSTON 5, JAMAICA, W.I. Tel: (876) 633-7400/7433/7771/8172/8174 Website: www.moh.gov.jm

#### APPENDIX 13: ENHANCED HOSPITAL SARI/ILI/aLRTI SURVEILLANCE REPORTING FORM

Parish:	Institution:	Epidemiological Week #:						Reporting: Daily 🛛		Weekly 🛛
		Surve	eillance of Seve	re Acute Res	piratory Infect	tion (SARI)				
Reporting Date:	< 6 mths	6-11 mths	12-23 mths	2-4 yrs	5-14 yrs	15-49 yrs	50-59 yrs	60-64 yrs	≥ 65 yrs	Total
SARI Admissions										
SARI Deaths										
SARI ICU Admissions										
Total ICU Admissions										
SARI Samples taken										
Hospital medical admissions										
Deaths in medical admissions										
Hospital Admissions										
Deaths in hospitalized patients										
SARI Entered into PAHO Flu										
UTM in Stock										

	Influenza-Like	e Illness (ILI)		Admitted Lower Respiratory Tract Infection (aLRTI)		
	Total	< 5 yrs	5-59 yrs	≥ 60 yrs		
ILI Cases					Total aLRTI	
ILI Samples Taken					Total aLRTI Sample Taken	
Total Visits					Total alk it sample Taken	

Surveillance Coordinator:

MO(H) Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Notes: - Please indicate by ticking the respective box whether the report is daily or weekly.

- The Epidemiological Week begins on a Sunday and ends on a Saturday. The date on Sunday is recorded as the Week Start Date.

- Hospital medical admissions constitute all admissions to the medical ward, medical admissions to the paediatric ward, and medical admissions to the intensive care unit (for each particular age group).

- Deaths in medical admissions constitutes all deaths on the medical ward, in medical patients on the paediatric ward, in medical patients in the intensive care unit

- Hospital admissions constitutes all admissions to hospital

- Deaths in hospitalized patients constitute all deaths in those admitted to hospital.

- Total visits constitute all visits to hospitals A&E

- Form should be submitted to the surveillance unit, along with other parish weekly surveillance reports.

Revised April 15, 2020. V17